Visible-light-induced synthesis of pH-responsive composite hydrogels for controlled delivery of the anticonvulsant drug pregabalin

Çevik, Özlem; Gidon, Dogan; Kızılel, Seda

doi:10.1016/j.actbio.2014.09.018

Cited by 53 publications

(39 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,9 Of these intelligent hydrogel materials, the pH-responsive ones are widely investigated because the pH value is a crucial environmental factor in human bodies. 6,10,11 In recent decades, natural polymers such as polysaccharides, have frequently been used to design intelligent hydrogel drug carriers (reserving drugs in a de-swollen state and releasing drugs in a swollen state) owing to their superior physiochemical and biological properties (e.g., biodegradability, renewability and biocompatibility). 12,13 However, polysaccharide-based hydrogel drug devices have two signicant inherent limitations: one is the poor mechanical strength, and the other is the lack of sustained release ability.…”

Section: Introductionmentioning

confidence: 99%

Cationic Salecan-based hydrogels for release of 5-fluorouracil

Wei

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Cationic Salecan-based hydrogels for release of 5-fluorouracil

Wei

et al. 2017

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…In the equation, k represents characteristic constants of hydrogel and n is the exponential coefficient, which describes the mode of transport mechanism. The value of n was calculated as 0.45 for Fickian diffusion and 0.89 for swelling‐controlled diffusion . Model fitting results for our system were illustrated in Figure b, which suggested Fickian mode of diffusion of the drug from targeted carriers both in the presence and absence of collagenase.…”

Section: Resultsmentioning

confidence: 77%

Quinacrine Mediated Sensitization of Glioblastoma (GBM) Cells to TRAIL through MMP-Sensitive PEG Hydrogel Carriers

et al. 2016

Self Cite

View full text Add to dashboard Cite

Overcoming drug resistance is a major challenge for cancer therapy. Tumor necrosis factor α-related apoptosis-inducing ligand (TRAIL) is a potent therapeutic as an activator of apoptosis, particularly in tumor but not in healthy cells. However, its efficacy is limited by the resistance of tumor cell populations to the therapeutic substance. Here, we have addressed this limitation through the development of a controlled release system, matrix-metalloproteinase (MMP)-sensitive and arg-gly-asp-ser (RGDS) peptide functionalized poly (ethylene-glycol) (PEG) particles which are synthesized via visible-light-induced water-in-water emulsion polymerization. Quinacrine (QC), a recently discovered TRAIL sensitizer drug, is loaded into the hydrogel carriers and the influence of this system on the apoptosis of a malignant type of brain cancer, glioblastoma multiforme (GBM), has been investigated in detail. The results suggest that MMP-sensitive particles are cytocompatible and superior to promote TRAIL-induced apoptosis in GBM cells when loaded with QC. Compared to QC and TRAIL alone, combination of QC-loaded PEG hydrogel and TRAIL demonstrates synergistic apoptotic inducing behavior. Furthermore, QC-loaded particles, but not QC or PEG-hydrogels alone, enhance apoptosis as is measured through expression of apoptosis-related genes. This system is promising to significantly improve the efficacy of chemotherapeutic drugs and suggests a combination treatment for GBM therapy.

show abstract

“…Triethanolamine, a viscous organic compound, used as a cross‐linker to create hydrogels with good mechanical stability, is safe to use at concentration below 5% in prolonged contact. (Cevik et al ., ; Safety assessment of Triethnolamine, )…”

Section: Discussionmentioning

confidence: 99%

Effect of Subgingivally Delivered 10% Emblica officinalis Gel as an Adjunct to Scaling and Root Planing in the Treatment of Chronic Periodontitis - A Randomized Placebo-controlled Clinical Trial

Grover¹,

Tewari²,

Sharma³

et al. 2016

Phytother. Res.

View full text Add to dashboard Cite

Emblica officinalis fruit possesses varied medicinal properties including cytoprotective antimicrobial, antioxidant, antiresorptive and antiinflammatory activity. The present study aimed to investigate the effect of subgingival application of indigenously prepared E. officinalis (Amla) sustained-release gel adjunctive to scaling and root planing (SRP) on chronic periodontitis. Forty-six patients (528 sites) were randomly assigned to control group (23;264): SRP +placebo gel and test group (23;264): SRP + 10% E. officinalis gel application. Periodontal parameters: plaque index, gingival index, probing pocket depth (PPD), clinical attachment level (CAL) and modified sulcus bleeding index (mSBI) were assessed at baseline, 2 and 3-month post-therapy. Forty patients (470 sites) completed the trial. When test and control sites were compared, significantly more reduction in mean PPD, mSBI, number of sites with PPD = 5-6 mm, PPD ≥ 7 mm, CAL ≥ 6 mm and greater CAL gain were achieved in test sites at 2- and 3-month post-therapy (p < 0.05). Locally delivered 10% E. officinalis sustained-release gel used as an adjunct to SRP may be more effective in reducing inflammation and periodontal destruction in patients with chronic periodontitis when compared with SRP alone. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

Visible-light-induced synthesis of pH-responsive composite hydrogels for controlled delivery of the anticonvulsant drug pregabalin

Cited by 53 publications

References 41 publications

Cationic Salecan-based hydrogels for release of 5-fluorouracil

Cationic Salecan-based hydrogels for release of 5-fluorouracil

Quinacrine Mediated Sensitization of Glioblastoma (GBM) Cells to TRAIL through MMP-Sensitive PEG Hydrogel Carriers

Effect of Subgingivally Delivered 10% Emblica officinalis Gel as an Adjunct to Scaling and Root Planing in the Treatment of Chronic Periodontitis - A Randomized Placebo-controlled Clinical Trial

Contact Info

Product

Resources

About